Sign in

    Ramakanth Swayampakula

    Managing Director and Equity Research Analyst at H.C. Wainwright & Co., LLC

    Ramakanth Swayampakula is a Managing Director and Equity Research Analyst at H.C. Wainwright & Co., LLC, specializing in healthcare and biotechnology equity research. He actively covers companies such as Abscis, Vor Biopharma, MediWound, Precigen, and Mirum Pharmaceuticals, maintaining a notable track record with a TipRanks 4-star rating, average returns ranging from 7.3% to 12.1%, and a success rate around 40%. Swayampakula began his Wall Street research career over a decade ago, having previously held analytical roles at leading investment firms prior to joining H.C. Wainwright. Professionally, he holds Series 7, 63, 86, and 87 securities licenses and is registered with FINRA.

    Ramakanth Swayampakula's questions to AETHLON MEDICAL (AEMD) leadership

    Ramakanth Swayampakula's questions to AETHLON MEDICAL (AEMD) leadership • Q1 2026

    Question

    Ramakanth Swayampakula from H.C. Wainwright & Co., LLC asked for the original rationale behind setting up a parallel trial in India, what measures are being taken to accelerate patient enrollment in the Australian study, and when the company plans to release efficacy data from the first patient cohort.

    Answer

    Chief Medical Officer Dr. Steven LaRosa explained that efforts to accelerate the Australian trial include adding two new sites, using clinical trial liaisons, and launching social media campaigns. He noted that while some observations from the first cohort's data may be shared in September, a complete understanding of dosing efficacy will require data from all three cohorts. CEO James Frakes reiterated the September timeline for initial observations.

    Ask Fintool Equity Research AI

    Ramakanth Swayampakula's questions to AETHLON MEDICAL (AEMD) leadership • Q4 2025

    Question

    Ramakanth Swayampakula from H.C. Wainwright & Co., LLC asked for specifics on the oncology trial, including the timeline for the second cohort, whether the amended protocol could accelerate enrollment, and the frequency of Data Safety Monitoring Board (DSMB) reviews. He also inquired about the trial protocol in India, the overall study completion timeline, the company's cash runway, and the data required to secure a partnership.

    Answer

    CEO & CFO James Frakes explained that the DSMB will meet between each cohort and that the amended protocol and recruitment at larger hospitals should help enrollment move "much faster." He confirmed the Indian trial currently uses the original monotherapy protocol. Frakes estimated the Australian trial could be fully completed, including the final report, in nine to twelve months. He acknowledged that Aethlon will need to raise more capital until it can secure grants or a partnership, which he hopes the current study's data will be sufficient to attract.

    Ask Fintool Equity Research AI

    Ramakanth Swayampakula's questions to Humacyte (HUMA) leadership

    Ramakanth Swayampakula's questions to Humacyte (HUMA) leadership • Q2 2025

    Question

    Ramakanth Swayampakula of H.C. Wainwright & Co., LLC inquired about the conversion rate from VAC initiation to actual orders, the typical timeline for this process, and the potential impact of the negative CMS NTAP decision on private payer reimbursement.

    Answer

    CCO BJ Scheessele and CEO Laura Niklason responded. Scheessele stated that 12 hospitals have ordered CIMVEST to date, with several reordering. He noted that the VAC approval and contracting process has lengthened to six to nine-plus months due to economic pressures and public attacks. Regarding the NTAP decision, both executives emphasized that private payers, who cover the majority of trauma patients, base decisions on clinical and health economic data. They believe Humacyte's strong value proposition in reducing costly complications will drive supplemental reimbursement from private payers, mitigating the CMS decision's impact.

    Ask Fintool Equity Research AI

    Ramakanth Swayampakula's questions to IPA leadership

    Ramakanth Swayampakula's questions to IPA leadership • Q4 2025

    Question

    The analyst inquired about the clinical development and monetization strategy for the company's GLP-one peptides, the revenue recognition timeline for the major oncology partnership, the impact of recent FDA guidance on the adoption of the Lens AI platform, and the status of the European facility divestiture and the Canadian facility's capacity.

    Answer

    The company plans to partner for the clinical development of its GLP-one asset after completing initial formulation and dose-response studies. Revenue from the oncology partnership is expected to be recognized starting in Q2 of fiscal '26, based on standard development milestones. The FDA's AI guidance has increased inbound traffic for services that bolster IND applications, a trend expected to continue. The European divestiture is in its final stages with a single buyer, and the Canadian facility has successfully absorbed the workload, supported by expansion and the full integration of LENS AI applications.

    Ask Fintool Equity Research AI

    Ramakanth Swayampakula's questions to IPA leadership • Q4 2025

    Question

    Ramakanth Swayampakula of H.C. Wainwright & Co., LLC inquired about several key strategic areas, including the clinical development and monetization plan for the company's GLP-1 peptides, the revenue recognition timeline for the $8 million oncology partnership, the impact of recent FDA guidance on the adoption of the LENSai platform, and the progress of the European facility divestiture.

    Answer

    CEO Jennifer Bath explained that the GLP-1 asset is being advanced with partners for manufacturing and formulation, with the goal of securing a financial sponsor for clinical trials rather than internal development. Regarding the oncology partnership, she noted that revenue recognition is not a lump sum and will begin to be visible in the second quarter of fiscal 2026, without any unusual deal-breaking milestones. Dr. Bath also confirmed a significant increase in inbound inquiries for the LENSai platform to bolster IND applications following FDA guidance changes. Finally, she stated the European divestiture is in its final stages with a single buyer, and the Canadian facility is experiencing record growth and is well-equipped to handle all programs.

    Ask Fintool Equity Research AI

    Ramakanth Swayampakula's questions to CORCEPT THERAPEUTICS (CORT) leadership

    Ramakanth Swayampakula's questions to CORCEPT THERAPEUTICS (CORT) leadership • Q1 2025

    Question

    Ramakanth Swayampakula sought to quantify the percentage increase in Korlym scripts filled in March and April versus the prior two months. He also asked about the price differential between branded Korlym and the authorized generic to better model the path to the company's full-year revenue guidance.

    Answer

    Sean Maduck, President of Endocrinology, did not provide a specific month-over-month percentage but highlighted that Q1 enrollments nearly doubled year-over-year. He stated the authorized generic has a 12% list price discount but net price varies by payer, reiterating that increased volume is expected to overwhelm the price impact and is factored into the $900-$950 million revenue guidance.

    Ask Fintool Equity Research AI

    Ramakanth Swayampakula's questions to Spectral AI (MDAI) leadership

    Ramakanth Swayampakula's questions to Spectral AI (MDAI) leadership • Q4 2024

    Question

    Ramakanth Swayampakula asked about the timeline for the pediatric study data, development milestones for the DeepView Snapshot M in 2025, and key learnings from the U.K. device placements over the past year.

    Answer

    Executive Chairman Dr. Michael DiMaio clarified that the pediatric data was already collected and merged with the adult data in the recently announced top-line results. For Snapshot M, he noted that military feedback is being incorporated for ruggedness testing in 2025. Dr. Jeffrey Carter, the study's PI, added that U.K. users are providing positive feedback comparing DeepView favorably to older technologies, which will help inform new care guidelines.

    Ask Fintool Equity Research AI